---
title: "Cybin Inc. (now Helus Pharma) files Form 25 to leave NYSE American"
url: "https://aibio.space/news/cybin-inc-now-helus-pharma-files-form-25-leave-nyse-american/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2026-01-02"
section: "Listings"
tickers: "NEO:HELP"
source: "https://www.sec.gov/Archives/edgar/data/1833141/000106299326000002/form25.htm"
summary: "The January 2, 2026 filing covers the company's common shares. It relies on the SEC rule for a voluntary withdrawal by the issuer."
---

By the aibio.space news desk.

Sources

- [Helus Pharma Inc. 25 (2026-01-02)](https://www.sec.gov/Archives/edgar/data/1833141/000106299326000002/form25.htm)

[HELP](https://aibio.space/companies/helus-pharma/)

2026-01-02

# Cybin Inc. (now Helus Pharma) files Form 25 to leave NYSE American

Tickers [HELP](https://aibio.space/companies/helus-pharma/)

The January 2, 2026 filing covers the company's common shares. It relies on the SEC rule for a voluntary withdrawal by the issuer.

## Key facts

- **Company**: Helus Pharma Inc. (NEO: HELP)

- **News type**: Listings

- **Primary source**: [Helus Pharma Inc. 25 (2026-01-02)](https://www.sec.gov/Archives/edgar/data/1833141/000106299326000002/form25.htm)

*A supreme court building with lit columns. CC0, via rawpixel. The picture shows the field, not the companies named.*

Cybin Inc. (now Helus Pharma Inc.) filed a Form 25 with the SEC on January 2, 2026. A Form 25 is the notice that a class of securities is being removed from listing and registration on a national exchange. The filing names NYSE American LLC as the exchange and the company's common shares as the class.

The company marked the box for 17 CFR 240.12d2-2(c). That rule covers a voluntary withdrawal by the issuer, meaning the company itself asks to end the listing. In the form, Cybin certifies that it has reasonable grounds to believe it meets all of the requirements for filing the Form 25. It also states that it has complied with the rules of the exchange and the requirements of the SEC rule that govern voluntary withdrawal.

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

HELP

Helus Pharma Inc.

NEO · Canada

Open the starter desk

## More in Listings

Listings

### [Propanc Biopharma faces Nasdaq delisting on bid price, plans to appeal](https://aibio.space/news/propanc-biopharma-faces-nasdaq-delisting-bid-price-plans-appeal/)

Oct 29, 2026

Listings

### [Reviva asks stockholders to approve reverse split of up to 1-for-100](https://aibio.space/news/reviva-asks-stockholders-approve-reverse-split-up-1-100/)

Oct 29, 2026

Listings

### [Nasdaq to delist Glucotrack shares after bid price exception ends](https://aibio.space/news/nasdaq-delist-glucotrack-shares-after-bid-price-exception-ends/)

Oct 28, 2026

---
Source page: https://aibio.space/news/cybin-inc-now-helus-pharma-files-form-25-leave-nyse-american/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Cybin Inc. (now Helus Pharma) files Form 25 to leave NYSE American", 2026-01-02, https://aibio.space/news/cybin-inc-now-helus-pharma-files-form-25-leave-nyse-american/